Dr. John Leonard Elected to Quintiles Transnational Holdings Inc. Board of Directors
February 06 2015 - 8:00AM
Business Wire
Quintiles Transnational Holdings Inc. (“Quintiles” or the
“Company”) (NYSE: Q) announced today that Dr. John Leonard, MD, has
been appointed to its Board of Directors, effective immediately.
Dr. Leonard will also serve as a member of the Audit and Governance
Committees of the Board.
Dr. Leonard serves as chief medical officer for Cambridge,
MA-based Intellia Therapeutics, a private biotech company, in a
position he has held since 2014. Prior to Intellia, Dr. Leonard
served as the chief scientific officer and senior vice president of
research and development at AbbVie Inc., a global pharmaceutical
company, since its spin-out from Abbott Laboratories in January
2013 until retiring from those positions at the end of 2013.
Prior to the formation of AbbVie, Dr. Leonard served as senior
vice president of global pharmaceutical research and development at
Abbott from 2008 to 2012. He has over 30 years of combined
experience in medicine, research and management including various
roles at Abbott beginning in 1992. Dr. Leonard also serves as a
director of Chimerix, Inc., a biopharmaceutical company based in
Durham, NC.
Dr. Leonard earned a bachelor’s degree in biochemistry from the
University of Wisconsin at Madison and a doctorate in medicine from
Johns Hopkins University in Baltimore, MD. He completed an
internship and residency in internal medicine at Stanford
University Hospital followed by a postdoctoral fellowship in
molecular virology at the National Institute of Allergy and
Infectious Diseases at the National Institutes of Health.
About Quintiles
Quintiles (NYSE: Q), a Fortune 500 company, is the world’s
largest provider of biopharmaceutical development and commercial
outsourcing services. With a network of more than 32,000 employees
conducting business in approximately 100 countries, we helped
develop or commercialize all of 2013’s top-100 best-selling drugs
on the market. Quintiles applies the breadth and depth of our
service offerings along with extensive therapeutic, scientific and
analytics expertise to help our customers navigate an increasingly
complex healthcare environment as they seek to improve efficiency
and effectiveness in the delivery of better healthcare outcomes. To
learn more about Quintiles, please visit www.quintiles.com.
Click here to subscribe to Mobile Alerts for Quintiles.
QuintilesMedia Relations:Phil Bridges, + 1-919-998-1653Mobile:
+1-919-457-6347phil.bridges@quintiles.comorInvestor Relations:Karl
Deonanan, +1-919-998-2789InvestorRelations@quintiles.com
Qimonda AG Ads (NYSE:QI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Qimonda AG Ads (NYSE:QI)
Historical Stock Chart
From Jul 2023 to Jul 2024